Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality

To evaluate the effectiveness of a well‐controlled programme of early detection and treatment of prostate cancer in the population of Tyrol, Austria, where such a programme of early detection and treatment was initiated in 1988 and where prostate‐specific antigen (PSA) testing was offered for free to all men aged 45–75 years from 1993.

[1]  R. Tibshirani,et al.  Generalized additive models for medical research , 1986, Statistical methods in medical research.

[2]  M. Zelen,et al.  Are primary cancer prevention trials feasible? , 1988, Journal of the National Cancer Institute.

[3]  P. McCullagh,et al.  Generalized Linear Models , 1992 .

[4]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[5]  P. McCullagh,et al.  Generalized Linear Models, 2nd Edn. , 1990 .

[6]  I. Thompson,et al.  Disease-specific survival following routine prostate cancer screening by digital rectal examination: corrected patient classification. , 1993, JAMA.

[7]  T. Tong,et al.  Cancer statistics, 1993 , 1993, CA: a cancer journal for clinicians.

[8]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[9]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[10]  R. Kane,et al.  Characteristics of prostate cancers detected in a multimodality early detection program , 1993 .

[11]  W. Catalona,et al.  The nature of prostate cancer detected through prostate specific antigen based screening. , 1994, The Journal of urology.

[12]  G. Murphy,et al.  Cost analyses of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society-National Prostate Cancer Detection Project. , 1994, The Journal of urology.

[13]  T. Stamey,et al.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. , 1994, The Journal of urology.

[14]  M. Koch,et al.  Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. , 1994, The Journal of urology.

[15]  J. Gohagan,et al.  The prostate, lung, colorectal, and ovarian cancer screening trial of the national cancer institute , 1995 .

[16]  D. Chan,et al.  Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. , 1998, The Journal of urology.

[17]  P. Walsh.  Anatomic radical prostatectomy: evolution of the surgical technique. , 1998, The Journal of urology.

[18]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[19]  J. Gohagan,et al.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.

[20]  Peter Boyle,et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001 .

[21]  G. Bartsch,et al.  Detection of prostate cancer with a microbubble ultrasound contrast agent , 2001, The Lancet.

[22]  G Bartsch,et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001, Urology.

[23]  Harry J de Koning,et al.  Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial , 2002, International journal of cancer.

[24]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[25]  H. D. de Koning,et al.  Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial , 2002, International journal of cancer.

[26]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[27]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[28]  J. Kopec,et al.  Screening with prostate specific antigen and metastatic prostate cancer risk: A population-based case-control study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  F. Schrōder,et al.  Screening for prostate cancer: have you had your cholesterol measured? , 2004, BJU international.

[30]  E. Schernhammer,et al.  Prostate cancer and prostate-specific antigen (PSA) screening in Austria , 2005, Wiener klinische Wochenschrift.

[31]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[32]  H. Klocker,et al.  Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk , 2005, The Prostate.

[33]  H. Klocker,et al.  Screening for prostate cancer: updated experience from the tyrol study , 2005, The Canadian journal of urology.

[34]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[35]  G. Bartsch,et al.  Radical retropubic prostatectomy: apical preparation and curtain dissection of the neurovascular bundle , 2005, BJU international.

[36]  Hans Garmo,et al.  Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer , 2011 .

[37]  A. Jemal,et al.  Geographic Patterns of Prostate Cancer Mortality and Variations in Access to Medical Care in the United States , 2005, Cancer Epidemiology Biomarkers & Prevention.

[38]  W. Catalona,et al.  476: Underdiagnosis and Overdiagnosis of Prostate Cancer , 2006 .

[39]  M. Luján,et al.  Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2006, European urology.

[40]  H. Klocker,et al.  473: Tyrolean Screening Study: Update 2005 - Stage Migration and Decrease of Mortality , 2006 .

[41]  W. Catalona,et al.  Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. , 2006, The Journal of urology.

[42]  K. Armstrong,et al.  Survival associated with treatment vs observation of localized prostate cancer in elderly men. , 2006, JAMA.

[43]  Y. McIntosh.  The Relationship between Perceived Personal Risk of getting Prostate cancer and Prostate-Specific Antigen (PSA) Screening , 2008 .